Want to see SE:VIMIAN full AI Analyst Report?
VIMIAN Stock Chart & Stats
kr26.90
-kr0.40(-1.09%)
At close: 4:00 PM EST
kr26.90
-kr0.40(-1.09%)
Day’s Range― - ―
52-Week Rangekr24.18 - kr35.90
Previous CloseN/A
Volume151.34K
Average Volume (3M)772.80K
Market Cap
kr18.37B
Enterprise Valuekr18.09K
Total Cash (Recent Filing)kr51.74M
Total Debt (Recent Filing)kr279.56M
Price to Earnings (P/E)45.9
Beta0.56
Next Earnings
Oct 22, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding527,058,530
10 Day Avg. Volume366,844
30 Day Avg. Volume772,803
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)2.10
Price to Sales (P/S)3.45
P/FCF Ratio16.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr33.00Price Target Upside22.68% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr475.43M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sustained increase in revenue indicates continued demand for Vimian’s veterinary products and services. Growth across pharmaceuticals, diagnostics, equipment and consumables supports a diversified base of professional animal-health customers.
Margin ExpansionSubstantial operating and net margin improvement shows stronger profitability and operating leverage. If maintained, the higher earnings base can improve resilience and support reinvestment across Vimian’s veterinary health businesses.
Lower LeverageThe reduction in leverage strengthens financial flexibility and lowers balance-sheet risk. A larger equity base and more manageable debt burden should give Vimian greater capacity to fund operations and strategic growth through changing market conditions.
Bears Say
Cooling Revenue GrowthThe recent slowdown in revenue growth raises the risk that future earnings expansion will rely increasingly on efficiency gains rather than broader demand. Sustained margin improvement may be harder if market penetration and volumes weaken.
Volatile Cash GenerationUneven cash conversion can reduce the reliability of internally generated funding. Negative operating cash flow in 2023 and weaker TTM free cash flow growth suggest exposure to working-capital movements or investment timing.
Moderate Shareholder ReturnsAlthough profitability is improving, mid-single-digit ROE indicates that the enlarged equity and asset base is not yet producing strong shareholder returns. This may constrain the long-term efficiency of reinvestment and capital deployment.
Vimian Group AB News
VIMIAN FAQ
What was Vimian Group AB’s price range in the past 12 months?
Vimian Group AB lowest stock price was kr24.18 and its highest was kr35.90 in the past 12 months.
What is Vimian Group AB’s market cap?
Vimian Group AB’s market cap is kr18.37B.
When is Vimian Group AB’s upcoming earnings report date?
Vimian Group AB’s upcoming earnings report date is Oct 22, 2026 which is in 58 days.
How were Vimian Group AB’s earnings last quarter?
Vimian Group AB released its earnings results on Jul 17, 2026. The company reported kr0.222 earnings per share for the quarter, missing the consensus estimate of kr0.299 by -kr0.078.
Is Vimian Group AB overvalued?
According to Wall Street analysts Vimian Group AB’s price is currently Undervalued.
Does Vimian Group AB pay dividends?
Vimian Group AB does not currently pay dividends.
What is Vimian Group AB’s EPS estimate?
Vimian Group AB’s EPS estimate is 0.29.
How many shares outstanding does Vimian Group AB have?
Vimian Group AB has 527,058,530 shares outstanding.
What happened to Vimian Group AB’s price movement after its last earnings report?
Vimian Group AB reported an EPS of kr0.222 in its last earnings report, missing expectations of kr0.299. Following the earnings report the stock price went up 3.687%.
Which hedge fund is a major shareholder of Vimian Group AB?
Currently, no hedge funds are holding shares in SE:VIMIAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimian Group AB
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
VIMIAN Stock 12 Month Forecast
Average Price Target
kr33.00
▲(22.68% Upside)
Technical Analysis
AddLife AB
―
CellaVision AB
―
Bactiguard Holding AB
―
Q-linea AB
―
Devyser Diagnostics AB
―








